Axitinib first-line treatment of papillary renal cell carcinoma
The majority of renal cell carcinomas (RCCs) are a subtype [...]
Individualised axitinib dosing for patients with metastatic kidney cancer
In the following video interview with Practice Update, Dr Nancy [...]
Evaluation of brain metastases in patients with kidney cancer treated with avelumab plus axitinib
In this video interview from Practice Update, Dr Eric Jonasch [...]
ASCO GU 2020: Immunotherapy combinations effective for brain metastases
Two small studies reported on patients whose kidney cancer had [...]
NICE draft guidance refuses pembrolizumab plus axitinib combination
The National Institute for Health and Care Excellence (NICE) have issued [...]
New first-line immunotherapy plus TKI combinations for metastatic kidney cancer
Approval of axitinib plus pembrolizumab and axitinib plus avelumab in [...]
Comparison of first-line immunotherapy combinations for advanced kidney cancer
In this paper, three clinical trials with immunotherapy combinations for [...]
European Commission approves avelumab plus axitinib combination for the first-line treatment of advanced kidney cancer
Based on the findings from the pivotal phase III JAVELIN [...]
ESMO 2019: Kidney cancer tumour shrinkage in patients who did not have surgery
This interview with Dr Monty Pal, Associate Professor from the [...]
ESMO 2019: First-line avelumab plus axitinib in sarcomatoid kidney cancer – results from JAVELIN Renal 101
Results from the JAVELIN Renal 101 study to evaluate avelumab [...]
